In reality, only 2 major reasons exist for administering chemotherapy to most patients with metastatic cancer: to help them live longer and/or to help them live better. In exchange for treatment-related toxic effects (as well as substantial time, expense, and inconvenience), chemotherapy can prolong survival for patients with a variety of—though not all—solid tumors. Chemotherapy may also improve quality of life (QOL) for patients by reducing symptoms caused by a malignancy. In this issue of JAMA Oncology, Prigerson and colleagues1 report some troubling trial results: chemotherapy administered to patients with cancer near the end of life achieved neither goal.
Blanke CD, Fromme EK. Chemotherapy Near the End of Life: First—and Third and Fourth (Line)—Do No Harm. JAMA Oncol. 2015;1(6):785–786. doi:https://doi.org/10.1001/jamaoncol.2015.2379
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: